Results 71 to 80 of about 76,287 (255)
GLP-1 and Its Role in Glycogen Production: A Narrative Review
BiomedicinesGlucagon-like peptide-1 (GLP-1) has emerged as a pivotal regulator in the management of glucose homeostasis, glycogen metabolism, and energy balance, positioning it as a critical therapeutic target for addressing obesity, metabolic syndrome, and type 2 ...
Joseph Lotosky +8 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and <18 years old as a single agent dosed once daily (QD) or in a fixed‐dose combination with metformin dosed twice daily (BID). We characterize canagliflozin pharmacokinetics in paediatric patients with T2DM, compare estimated individual and simulated ...
Nele Goeyvaerts +6 more
wiley +1 more source
The Cardiovascular Biology of Glucagon-like Peptide-1 [PDF]
Cell Metabolism, 2016 Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose metabolism and energy homeostasis through regulation of islet hormone secretion, gastrointestinal motility, and food intake, enabling development of GLP-1 receptor (GLP-1R) agonists for the treatment of diabetes and obesity.
openaire +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon +7 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster +10 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang +5 more
wiley +1 more source
Journal of Traditional and Complementary MedicineBackground and aim: Curcumin has shown significant cardiovascular protective effects. However, the low bioavailability limits its practical application. As a natural bioenhancer, piperine is expected to increase the bioavailability of curcumin, and then,
Xiao-jie Bai +7 more
doaj +1 more source
Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes [PDF]
Electronic Physician, 2013 :Background: The aim of this study was to examine the effect of purslane seeds in glucagon-like peptide-1 concentration and glucagon-like peptide-1 receptor in women with diabetes.Methods: This was a quasi-experimental study. The population was consisted
Roja Daliri +3 more
doaj
New therapeutic options for metabolic‐associated steatotic liver disease
British Journal of Clinical Pharmacology, EarlyView.An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley +1 more source